Photocure ASA (OSL:PHO)

Norway flag Norway · Delayed Price · Currency is NOK
49.80
-0.20 (-0.40%)
May 12, 2025, 4:25 PM CET
-13.84%
Market Cap 1.33B
Revenue (ttm) 532.69M
Net Income (ttm) 2.14M
Shares Out 26.61M
EPS (ttm) 0.08
PE Ratio 619.74
Forward PE 331.25
Dividend n/a
Ex-Dividend Date n/a
Volume 93,235
Average Volume 44,070
Open 50.00
Previous Close 50.00
Day's Range 48.75 - 50.10
52-Week Range 47.00 - 69.00
Beta 0.62
RSI 36.56
Earnings Date Jul 30, 2025

About Photocure ASA

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreemen... [Read more]

Sector Healthcare
Founded 1993
Employees 101
Stock Exchange Oslo Børs
Ticker Symbol PHO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.